	US 12,226,492 B2
	Gene therapy for eosinophilic disorders
Ronald G. Crystal, New York, NY (US); Odelya E. Pagovich, New York, NY (US); and Katie Stiles, Bronx, NY (US)
Assigned to Cornell University, Ithaca, NY (US)
Appl. No. 16/959,090
Filed by Cornell University, Ithaca, NY (US)
PCT Filed Dec. 28, 2018, PCT No. PCT/US2018/067869 § 371(c)(1), (2) Date Jun. 29, 2020, PCT Pub. No. WO2019/133818, PCT Pub. Date Jul. 4, 2019.
Claims priority of provisional application 62/612,005, filed on Dec. 29, 2017.
Prior Publication US 2020/0330608 A1, Oct. 22, 2020
Int. Cl. C07K 16/44 (2006.01); A61K 48/00 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)

CPC A61K 48/005 (2013.01) [A61K 48/0075 (2013.01); C07K 16/2851 (2013.01); C07K 16/44 (2013.01); C12N 15/86 (2013.01); C12N 2750/14143 (2013.01)]

20 Claims

1. A method of inhibiting or treating leukemia in a mammal, comprising:

administering to the mammal a composition comprising a recombinant adeno-associated virus (rAAV) expression vector comprising an open reading frame encoding an antibody that binds sialic acid binding Ig-like lectin 8, in an amount effective to inhibit or treat the leukemia, wherein the open reading frame encodes a sequence having three CDRs of SEQ ID Nos. 5 and 29.